Stavros Stavrakis, MD
Cardiovascular Disease · Oklahoma City, OKNPI 1467593152
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (53.0%), consulting fees and travel and lodging — rather than concentrated in one kind of arrangement. 18 manufacturers reported payments, led by Biosense Webster, Inc. at 27.8% of the total.
Across 74 payments — averaging $86.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Biosense Webster, Inc.$2K
- E.r. Squibb & Sons, L.L.C.$2K
- Medtronic$1K
- Janssen Research & Development, LLC$776
- Abiomed$145
- Regeneron$92
- plus $558 from 12 others
Across 88 payments — averaging $1910.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$128K
- Janssen Research & Development, LLC$41K
What the payments were for
- Consulting fees$1,62525%
- Travel & lodging$1,36821%
- Food & beverage$3,38053%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Biosense Webster, Inc. | 15 | $1,769 |
| E.r. Squibb & Sons, L.L.C. | 4 | $1,728 |
| Medtronic(2 entities) | 23 | $1,305 |
| Janssen Research & Development, LLC | 8 | $776 |
| Abiomed | 1 | $145 |
| Regeneron | 2 | $92 |
| Microport CRM USA Inc | 1 | $84 |
| Pulmonx Corporation | 2 | $79 |
| Baxter Healthcare | 2 | $75 |
| Novartis | 3 | $61 |
| Kestra Medical Technology Services, Inc. | 3 | $59 |
| Johnson & Johnson(2 entities) | 2 | $48 |
| Cardiva Medical, Inc. | 2 | $47 |
| Bardy Diagnostics, Inc. | 2 | $29 |
| Merck | 1 | $23 |
| Stryker | 1 | $18 |
| Pfizer | 1 | $17 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ELIQUIS$1,625
- Carto 3$1,126
- Micra$567
- QDOT MICRO Catheter$192
- Impella$145
- Claria MRI$137
- Carto 3 System$109
How this compares
$6,373 in reported general payments places this provider in the 70th percentile of 164 cardiovascular disease providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 122 | $160,396 |
| MultaqDronedarone Hcl | 28 | $42,921 |
| JardianceEmpagliflozin | 19 | $24,258 |
| XareltoRivaroxaban | 30 | $23,858 |
| Dofetilide | 31 | $4,852 |
| Propafenone Hcl ErPropafenone Hcl | 17 | $2,263 |
| Flecainide Acetate | 21 | $909 |
| Metoprolol Succinate | 67 | $837 |
| Midodrine Hcl | 12 | $604 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 11 | $390 |
| Diltiazem 24hr Er (Cd)Diltiazem Hcl | 19 | $333 |
| Amlodipine Besylate | 33 | $317 |
| Amiodarone Hcl | 37 | $302 |
| Atorvastatin Calcium | 17 | $269 |
| Lisinopril | 26 | $263 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $17 | $160,396122 claims |
| Johnson & JohnsonXarelto | $48 | $23,85830 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 164 cardiovascular disease providers in Oklahoma.
Other cardiovascular disease in Oklahoma City
- Aly El BanayosyOklahoma City$54K
- Dwight ReynoldsOklahoma City$47K
- Udho ThadaniOklahoma City$41K
- Robert SullivanOklahoma City$36K
- Reji PappyOklahoma City$25K
- Sandeep ChopraOklahoma City$15K
- Jered CookOklahoma City$14K
- William CollazoOklahoma City$11K
- Vinodh JeevananthamOklahoma City$11K
- Niraj PrasadOklahoma City$10K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.